Brain cancer is treated with a combination of surgery, radiation, chemotherapy, and newer approaches like electric field therapy and immunotherapy. The exact plan depends on the tumor type, its location, its molecular profile, and the patient’s overall health. Most people receive more than one type of treatment, often in a specific sequence designed to remove as much tumor as possible and then target whatever remains.
How Tumor Type Shapes the Treatment Plan
Not all brain tumors are the same, and modern diagnosis goes well beyond looking at cells under a microscope. The current classification system, updated in 2021, relies heavily on molecular markers: specific genetic mutations within the tumor that influence how aggressive it is and how well it responds to treatment. Two of the most important markers are IDH mutation status and a chromosomal change called 1p/19q codeletion. Tumors with certain favorable mutations tend to grow more slowly and respond better to chemotherapy and radiation, while tumors lacking those mutations, like most glioblastomas, are more aggressive and harder to treat.
This molecular profiling is why two people with tumors that look identical on a brain scan can end up with very different treatment plans. Your medical team will use biopsy tissue to run these genetic tests before finalizing your course of treatment.
Surgery: The First Line of Treatment
For most brain cancers, surgery is the starting point. The goal is to remove as much of the tumor as possible, a concept called extent of resection. Removing a greater percentage of the tumor is linked to longer survival, better seizure control, and improved quality of life. It also makes subsequent radiation and chemotherapy more effective because there’s less tumor left to treat.
Complete removal isn’t always possible. Brain tumors often grow into areas that control speech, movement, or vision. Surgeons use real-time brain mapping and imaging during the operation to remove the maximum amount of tumor while preserving critical functions. When a tumor sits in an area that’s too risky for open surgery, a minimally invasive option called laser interstitial thermal therapy (LITT) may be used instead. LITT uses a small probe inserted through a tiny incision to heat and destroy tumor tissue. Hospital stays are typically one to two days, recovery is faster than open surgery, and patients can start follow-up treatments sooner.
Radiation Therapy
Radiation is used after surgery to kill remaining cancer cells, or as a primary treatment when surgery isn’t an option. The two main approaches differ in how precisely they deliver energy to the tumor while sparing healthy brain tissue.
Standard radiation therapy delivers targeted beams over several weeks, typically five days a week for about six weeks. Stereotactic radiosurgery is a more focused technique that delivers a high dose of radiation in one or a few sessions, making it well suited for smaller tumors or metastases. It offers excellent precision for irregularly shaped targets or tumors near critical structures like the brainstem or optic nerves.
Proton therapy is a newer option that uses charged particles instead of traditional X-ray beams. Its main advantage is that protons deposit most of their energy directly in the tumor and deliver very little radiation to tissue beyond it. This substantially reduces low-dose exposure to surrounding healthy brain, which is particularly valuable in children (whose brains are still developing) and in tumors sitting right next to sensitive structures. Proton therapy does have a small margin of uncertainty, around 2 to 3 millimeters, which matters when treating very small targets.
Chemotherapy and the Standard Protocol
For glioblastoma, the most common and aggressive primary brain cancer, the standard treatment after surgery follows a well-established sequence. During six weeks of daily radiation, you take an oral chemotherapy drug at a lower dose every single day, including weekends. After radiation ends, there’s a brief break before starting maintenance cycles: five days of the same drug at a higher dose, followed by 23 days off. This cycle repeats monthly for at least six months, sometimes up to a year.
One of the biggest challenges with treating brain cancer is the blood-brain barrier, a tightly sealed network of blood vessels that prevents most drugs from entering the brain. This barrier is why many chemotherapies that work well against cancers elsewhere in the body are ineffective against brain tumors. Researchers are actively working on ways to temporarily open this barrier to let drugs through.
Getting Drugs Past the Blood-Brain Barrier
Two techniques show real promise. The first uses a concentrated sugar solution infused into an artery to temporarily shrink the cells lining brain blood vessels, widening the gaps between them for a short window. In clinical trials for brain metastases, this approach combined with chemotherapy extended median survival to 13.5 months compared to a historical range of just 2 to 4 months.
The second technique, MRI-guided focused ultrasound, is completely noninvasive. Tiny microbubbles are injected into the bloodstream, and focused ultrasound waves cause them to vibrate against blood vessel walls, temporarily loosening the tight seals. Doctors can watch this process in real time on MRI and adjust as needed. Early trials have shown a 10 to 15 percent increase in drug penetration with no serious side effects, and the barrier reseals itself within about 20 hours.
Tumor Treating Fields
Tumor Treating Fields (TTFields) is a treatment unique to brain cancer. You wear adhesive electrode arrays on your shaved scalp for at least 18 hours a day. These arrays deliver low-intensity alternating electric fields at a specific frequency (200 kHz) that interfere with cell division. Because cancer cells divide far more rapidly than normal brain cells, the electric fields selectively disrupt tumor growth.
When added to standard chemotherapy for newly diagnosed glioblastoma, TTFields extended median survival from 16 months to nearly 21 months. The treatment is portable, so you can go about most daily activities while wearing the device. The main downsides are skin irritation where the arrays attach and the social aspect of wearing a visible medical device.
Targeted Therapy
Some brain cancers are treated with drugs that target specific biological pathways fueling tumor growth. One widely used approach for recurrent glioblastoma blocks a signaling molecule called VEGF that tumors use to build new blood vessels and sustain their growth. This drug is given intravenously every two to three weeks. It can reduce swelling and shrink tumors on imaging, though the effect on long-term survival remains debated since some of the apparent shrinkage on scans reflects reduced swelling rather than true tumor destruction.
Immunotherapy and CAR T-Cell Research
Immunotherapy, which harnesses the body’s own immune system to attack cancer, has transformed treatment for many cancers but has been slower to show results in the brain. The blood-brain barrier and the brain’s unique immune environment make it harder for immune-based treatments to reach and fight tumors there.
The most encouraging recent results come from CAR T-cell therapy, where a patient’s own immune cells are removed, engineered in a lab to recognize a specific molecule on the tumor surface, and then infused back. A Stanford-led trial tested this approach in children with a deadly type of brain tumor called diffuse midline glioma. Of 11 patients treated, 9 showed neurological improvement and 7 had measurable tumor shrinkage. After two and a half years, tumors shrank by more than half in 4 patients, and one patient’s tumor disappeared entirely and has not returned. Other trials are now testing CAR T cells engineered to target different molecules on both childhood and adult brain tumors.
Managing Symptoms and Swelling
Brain tumors cause symptoms not just from the cancer itself but from the swelling they create in surrounding tissue. This swelling increases pressure inside the skull, leading to headaches, nausea, weakness, or confusion. Corticosteroids are the standard treatment to reduce this swelling quickly. Most patients with mild symptoms respond within 24 to 72 hours on a starting dose, with higher doses reserved for more severe symptoms. These medications are meant for short-term use and are typically tapered over about four weeks to avoid side effects like weight gain, elevated blood sugar, and muscle weakness.
Recovery and Rehabilitation
Brain cancer treatment can affect movement, balance, speech, memory, and the ability to handle everyday tasks. Rehabilitation usually begins soon after surgery and continues throughout treatment. Physical therapy focuses on regaining strength, coordination, and balance. Occupational therapy helps you relearn daily tasks like dressing, cooking, or using a computer. Speech and language therapy addresses difficulties with speaking, swallowing, or word-finding that can result from surgery or radiation near language centers.
Most patients see significant improvement within three to six months. Full recovery, including cognitive and emotional healing, can take a year or longer depending on the tumor’s location, the extent of surgery, and overall health before treatment. Recovery is not always linear. Some abilities return quickly while others improve gradually, and rehabilitation goals often shift as treatment progresses.
Survival by the Numbers
Survival rates for brain cancer vary enormously by tumor type and age. Glioblastoma, the most aggressive form, has a five-year survival rate of about 5.6% for adults over 40. Younger patients fare better: 27.3% for those aged 15 to 39, and 19.5% for children under 14. Lower-grade tumors with favorable molecular profiles carry significantly better outlooks, with many patients living years or even decades after diagnosis. These statistics reflect older data and don’t yet capture the impact of newer treatments like TTFields, molecular-guided therapies, and emerging immunotherapies.